Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasrallah, Sami N., Reynolds, L. Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Concise Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411522/
https://www.ncbi.nlm.nih.gov/pubmed/22879797
http://dx.doi.org/10.4137/CMED.S9494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411522/
https://www.ncbi.nlm.nih.gov/pubmed/22879797
http://dx.doi.org/10.4137/CMED.S9494

Ejemplares similares